Dr. Hutson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
602 Indiana Avenue
Lubbock, TX 79415Phone+1 806-775-8600
Summary
- Dr. Thomas E Hutson is recognized internationally as a leader in the field of urologic cancers, has authored over 500 scholarly works which includes original research, monographs and book chapters, is regularly invited to speak at medical venues around the world, and has been the clinical lead investigator on several international research trials. He has had leadership roles in several national research groups including the Sarah Cannon Research Institute where he continues to serve on the GU Research Executive Committee and co-leads the Phase 1b/2 clinical trial program. He is the editor in chief of the Kidney Cancer Journal and serves on the editorial boards of Expert Review of Anticancer Therapy, Cure, among others. Dr. Hutson practiced at Baylor University Medical Center in Dallas, Texas for 21 years and served as the Co-Director of the Urologic Cancer Research and Treatment Center as well as the Director of the Swim Across America supported Innovative Clinical Trial Center.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2001 - 2004- Cleveland Clinic FoundationResidency, Internal Medicine, 1997 - 2000
Ohio University Heritage College of Osteopathic Medicine in AthensClass of 1997
Certifications & Licensure
TX State License 2003 - 2026
OH State License 1993 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Top Doc
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACP) American College of Physicians, 2007
Clinical Trials
- Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 651 citationsCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialToni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring
The Lancet. Oncology. 2016-07-01 - 295 citationsPharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaKerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, Rene Gonzalez, Grant A. McArthur
Journal of Clinical Oncology. 2013-05-10 - 749 citationsRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Fei Su, Amaya Viros, Carla Milagre, Kerstin Trunzer, Gideon Bollag
The New England Journal of Medicine. 2012-01-18
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
- Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
- Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell CarcinomaMichael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
Press Mentions
Managing Side Effects of Kidney Cancer TreatmentsDecember 13th, 2022- Dr. Thomas Hutson: Clearing the Record on Kidney CancerApril 7th, 2020
Active Lifestyles May Help Nerves to Heal After Spinal InjuriesMay 7th, 2019- Join now to see all
Committees
- GU Research Committee, Southwest Oncology Group
- Co Lead- Bridge Program (Phase Ib and II), Sarah Cannon Research Institute
- Executive Committee Member, GU Research, Sarah Cannon Research Institute
Professional Memberships
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
